{
    "clinical_study": {
        "@rank": "8294", 
        "arm_group": [
            {
                "arm_group_label": "Healthy subjects", 
                "description": "Self-explanatory"
            }, 
            {
                "arm_group_label": "Untreated patients", 
                "description": "Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS"
            }, 
            {
                "arm_group_label": "Treated patients", 
                "description": "Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment"
            }
        ], 
        "biospec_descr": {
            "textblock": "peripheral blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported\n      in many human diseases. The purpose of this pilot study is to determine if microRNA\n      expression is changed in untreated and glatiramer acetate-treated patients with multiple\n      sclerosis."
        }, 
        "brief_title": "Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported\n      in many human diseases. The purpose of this pilot study is to determine if microRNA\n      expression is changed in untreated and glatiramer acetate-treated patients with multiple\n      sclerosis. The expression of microRNA will be analysed in cell subsets separated from\n      peripheral blood mononuclear cells."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        18-60 year-old healthy subjects or patients with RRMS/CIS\n\n        Exclusion Criteria:\n\n          1. Any treatment with steroids in the last 30 days prior to the blood draw or any\n             immunosuppressive or Disease-modifying treatment (DMT) other than Glatiramer Acetate\n             in the last 90 days\n\n          2. Presence of other disorders that may be associated with immune-deficient or\n             autoimmune process (e.g., HIV, lymphoma, lupus) or demyelinating disease other than\n             MS (e.g., Lyme, B12 deficiency)\n\n          3. Pregnancy\n\n          4. Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk\n             about 100 meters with or without resting (Expanded Disability Status Scale (EDSS)\n             score greater than 5.5)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Control human subjects and patients with RRMS will be enrolled in New Brunswick, NJ"
            }
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993004", 
            "org_study_id": "IRB0220060134"
        }, 
        "intervention_browse": {
            "mesh_term": "Copolymer 1"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "contact": {
                "email": "konstantin.balashov@rutgers.edu", 
                "last_name": "Konstantin Balashov, MD, PhD, FAAN", 
                "phone": "732-235-7727"
            }, 
            "facility": {
                "address": {
                    "city": "New Brunswick", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08901"
                }, 
                "name": "Rutgers-RWJMS"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells", 
        "overall_contact": {
            "email": "konstantin.balashov@rutgers.edu", 
            "last_name": "Konstantin Balashov, MD, PhD, FAAN", 
            "phone": "732-235-7727"
        }, 
        "overall_official": {
            "affiliation": "Rutgers-RWJMS", 
            "last_name": "Konstantin Balashov, MD, PhD, FAAN", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Expression of multiple microRNA is being tested in B cells in three groups of subjects at one time point", 
            "measure": "Relative MicroRNA expression in B cells", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993004"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rutgers, The State University of New Jersey", 
            "investigator_full_name": "Konstantin Balashov", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Rutgers, The State University of New Jersey", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rutgers, The State University of New Jersey", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}